Multicentre study of gestrinone in cyclical breast pain FRIEDOLF PETERS

The Lancet

Volumn 339, Issue 8787, 1992, Pages 205-208

  Peters, F ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GESTRINONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MASTALGIA; MENSTRUAL CYCLE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; BREAST DISEASES; DOUBLE-BLIND METHOD; ESTRADIOL; FEMALE; FOLLOW-UP STUDIES; GESTRINONE; HUMAN; MIDDLE AGE; PAIN; PERIODICITY; PROGESTERONE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TRIIODOTHYRONINE;

EID: 0026599732     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/0140-6736(92)90005-N     Document Type: Article

References (27)

1. Clinical syndromes of mastalgia
2. Hormones and the pathophysiology of fibrocystic mastopathy
3. Inadequate corpus luteal function in women with benign breast diseases
4. Serum progesterone concentration during the luteal phase in women with benign breast disease
5. Evaluation of luteal-phase salivary progesterone levels in women with benign breast disease or primary breast cancer
6. PRL, TSH, and thyroid hormones in benign breast diseases
7. Serum prolactin levels in patients with fibrocystic breast disease
8. Serum prolactin and oestradiol levels in women with cyclical mastalgia
9. Serum oestradiol-17β and prolactin concentrations during the luteal phase in women with benign breast disease
10. Hormonal characterization of benign breast diseases: a re-evaluation
11. Cyclical mastopathy: a critical review of therapy
12. Gestrinone (E2323) binding to steroid receptors in human uterine endometrial cytosol
13. A new approach to estrogen-free contraception based on progesterone receptor blockage by mid-cycle administration on ethyl norgestrinone (R2323)
14. Cyclical evaluation of an oral progestin contraceptive, R 2323 5 mg administered at weekly intervals
15. Three-step therapy of genital endometriosis in cases of human infertility with lynestrenol, danazol, or gestrinone administration in the second step
16. Regression of uterine leiomyomas after treatment with gestrinone, an antiestrogen, antiprogesterone
17. Oral gestrinone: a novel antiprogestin with no antitumor activity in endocrine-sensitive breast cancer
18. Ultrasonographic and hormonal studies in physiologic and insufficient menstrual cycles
19. The effect of danazol on the pituitary function, thyroid function and mastodynia
20. Endocrine effects of gestrinone
21. Endocrine, metabolic, and clinical effects of gestrinone in women with endometriosis
22. Steroid receptors and pharmacology
23. Dynamics of the receptor interactions of danazol and gestrinone in the rat: correlation with biological activities
24. Studies on the mechanism of action of danazol and gestrinine (R2323) in the rat: evidence for a masked estrogen component
25. European multicentre trial of bromocriptine in cyclical mastalgia
26. Controlled trial of the antigonadotropin danazol in painful nodular benign breast disease
27. Double-blind controlled trial of tamoxifen therapy for mastalgia